Navigation Links
Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
Date:9/28/2007

CARMIEL, Israel, Sept. 28 /PRNewswire-FirstCall/ -- The Russell Investment Group has advised Protalix Biotherapeutics (Amex: PLX) that there will be a float weight adjustment effective after the close of trading on September 28, 2007 in the following indexes: Russell 2000, Russell 2000 Growth, Russell 2500, Russell 2500 Growth, Russell Global Small Cap, Russell 3000, Russell 3000 Growth, Russell Small Cap Completeness and the Russell Small Cap Completeness Growth.

About Protalix BioTherapeutics, Inc.

Protalix is a clinical stage biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based protein expression system, ProCellEx(TM). ProCellEx presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix has initiated enrollment and treatment of patients in its pivotal phase III clinical trial of its lead product candidate, prGCD, for enzyme replacement therapy of Gaucher disease, a lysosomal storage disorder in humans. The final design of the pivotal phase III clinical trial is based on an agreement reached by Protalix with the United States Food and Drug Administration, through its Special Protocol Assessment (SPA). Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.

For additional information, contact Protalix BioTherapeutics at: investors@protalix.com


'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Russell Killer Bids To Halt Publication Of Mental Health Report
2. China Doubles Its Investment In AIDS/HIV Treatment.
3. Biocon To Raise Its Investment In Scotland
4. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
5. Varicose Vein Treatments Turn Out To Be A Viable Health Investment
6. WHO calls for big investment in tests for TB
7. China Opens Doors For Foreign Investments In Hospitals Care System
8. Fidel Castro Appeals for Investment in Health Rather Than in Arms
9. No link between blood groups and prostate cancer
10. Consumer group seeks Sibutramine ban
11. Suicide risk high in 12-17 Age Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , ... August 17, 2017 , ... ... (ER) on Wednesday, August 16, to community partners. The newly renovated ER was ... Track” area for minor emergencies, eight semi-private rooms to deliver patient results, improve ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, ... trauma, to encourage inner healing of memories and achieve forgiveness, through a progressive ...
(Date:8/17/2017)... ... ... digital marketing for medical practices, has been recognized as one of the fastest growing privately ... second time in two years. Shawn Miele, Chief Executive Officer of Advice Media, said, “We ... a row. It’s extremely difficult to make this list once. The fact that we made ...
(Date:8/16/2017)... ... ... Summer days spent with family are priceless. Since August is Family Fun ... the season of sunshine. Add trying something new to this summer’s bucket list. Whether ... the fun. , Try Something New , Choose an activity the ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Ten outstanding teachers ... Stars in the Classroom and will win a visit by a Houston Texans player, ... who are at least five years old can visit texanschecking.com/stars to nominate their favorite ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... July 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... ended June 30, 2017.  The Company reported second quarter ... over the prior year period, and an increase of ... basis points of contribution from the LDR Holding Corporation ... second quarter of 2016, or 0.3% on a constant ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/25/2017)... Spain and CAMBRIDGE, Massachusetts , ... Biotech, specializing in repurposing drugs to treat rare nervous system ... Inc. to clinically develop and market the drug SOM0226 against ... the drug achieved very promising results in a Phase 2 ... A new office in the United States ...
Breaking Medicine Technology: